TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline in Weekly Average of Daily Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete response (CR) rate at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Completion of seven-day course of amiodarone
Endpoint domain: Adverse events/effects
Primary endpoint: sRAGE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in VExUS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mixed venous oxygen saturation (SvO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response of Much Improved or Very Much Improved on the PGIC Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: LPA1 occupancy in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: LPA1 occupancy in the lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Preference regarding starting medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stopping medication
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants who Experience Tumor Lysis Syndrome (TLS)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in WURSS-21 Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline in WURSS-21 Total Symptom Domain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in WURSS-21 Total QoL Domain Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the plasma-concentration time curve from time zero to infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cornea thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving DLQI 0 or 1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prognosis of ovarian leiomyosarcoma
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve of Moxidectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of the Wisconsin Upper Respiratory Symptoms Survey for Kids (WURSS-K)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival abrasion macro-relief scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life in Late-Stage Dementia
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Myofibrillar fractional synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Half-life (t½) of Warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) and/or Recommended Phase II Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean sum PHQ-8 somatic item scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline acne scar severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dermatology Quality of Life Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Resting-state functional connectivity (FC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood oxygenation level dependent (BOLD) activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Applied Cognition-General Concerns scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Hypoglycemic Confidence Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hypoglycemia Fear Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hypoglycemia Attitude and Behavior Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Hypoglycemia Awareness Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: threshold pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KOOS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Prolonged Grief Disorder-13-R (PG-13-R) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Center for Epidemiologic Studies Depression Scale - Revised (CESD-R) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ischemic endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bleeding endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Post-Operative Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of intracranial hemorrhage and/or worsening of edema
Endpoint domain: Adverse events/effects
Primary endpoint: Voice and speech rehabilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attrition Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence Rate
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Acceptability Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Wang bronchiolitis clinical score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Opiate Withdrawal Scale (COWS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Tear Breakup Time (TBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-∞]) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VP Shunt Complication Follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Hydrocephalus Knowledge and Care Skills Self-Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Noise-induced awakening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of local injection site reactogenicity signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Tinnitus Primary Functions Questionnaire (TPFQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Behavioral Approach Task - Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Behavioral Approach Task - Skin Conductance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age of pubertal onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of males and females with delayed puberty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Age at the time of the presence of dosable serum LH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Achievement of stable pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area of new bone tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rates of positive margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy of Accuhaler tester
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Ellipta tester
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Turbutester
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Quality Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Measure of Portal Vein Flow Pulsality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricular (RV) function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain intensity assessment
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Sensitivity of lung contusion detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Psychological Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Negative Symptom change, PANSS negative subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative Symptom change, Brief Negative Symptom Scale (BNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in body image flexibility
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in High Frequency Heart Rate Variability (HF-HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in biased processing of body image stimuli
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the level of Cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change from Baseline of Vaginal Health Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS pain Score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Glutathione Peroxidase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Superoxide Dismutase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grasp performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic anomalies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relative quantitative of small non-coding RNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cultural Awareness Scale (CAS) Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Clinical Interpersonal Reactivity Index (CIRI) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Radiological progression-free survival (rPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Average score change in RDQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Speech in noise perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-valent HPV genotype prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 1-year allograft outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year PFS rate
Endpoint domain: Mortality/survival
Primary endpoint: 3-year OS rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in TSPO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory cytokines in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biological changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hs-cTn level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physiological parameters- heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological parameters- oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological parameters- respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: structured theoretical exam scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Case Test Scores on Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-ERCP complications
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of HCC recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Proteomic signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating adipocyte-derived extracellular vesicles (Ad-EVs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General and eye-related physical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VR experience tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of the VR apparatus
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent change in CD8+ T cell infiltrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual Analog Scale (VAS) pain measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic profile comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parameters of ventilatory mechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rate of termination of hiccup in 30 seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time course from the start of therapy to the end of hiccup
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of upper extremity functional capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Cardiovascular Endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effective rates of prevention of diaphragmatic elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Success in correcting diaphragmatic elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ratio of Geometric Mean Titers (rGMT) of antibodies induced by QIV-IB/0.25ml compared to TIVV-IB and TIVY-IB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ratio of Geometric Mean Titers (rGMT) of antibodies induced by QIV-IB/0.50ml compared to TIVV-IB and TIVY-IB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ratio of Geometric Mean Titers (rGMT) of antibodies induced by QIV-IB/0.25ml compared to TIV that does not contain the B strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects not progressing to Stage 3 of herpes labialis outbreak
Endpoint domain: Mortality/survival
Primary endpoint: Headache Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Changes of Accuracy in Wisconsin Card Sorting Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to First Occurrence of Composite Endpoint of End Stage Kidney Disease (ESKD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ≥ 40% Sustained Decline in Estimated Glomerular Filtration Rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: CV Death or Renal Death
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of subjects with treatment-emergent adverse events assessed as drug-related
Endpoint domain: Adverse events/effects
Primary endpoint: Melatonin concentration in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sIgA concentration in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of severe immune-related adverse event (irAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Performance scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Stability of the implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autism Impact Measure (AIM)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Attentional bias to e-cigarette cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Ethinyl Estradiol (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cmax of Drospirenone (DRSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC0-τ) of EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in Alcohol use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Progressive retinal axonal loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 2-year Disease-Free Survival Rate (2yDFSR)
Endpoint domain: Mortality/survival
Primary endpoint: 2-year Overall Survival Rate (2yOSR)
Endpoint domain: Mortality/survival
Primary endpoint: DMS-PCAD score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of colonoscopies
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants Experiencing Late-onset Targeted Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Late-onset Targeted Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Sexual Maturation of Pediatric and Adolescent Participants Assessed by Tanner Pubertal Stage Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epinephrine levels (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Towler questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Erectile function as measured by the IIEF-EF questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Objective Response Rate (ORR) of GEN3014
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes from baseline PHQ-15 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline HAQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regularity of use of eMind
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Qualitative detection of RNA from SARS-CoV-2, Influenza A, and Influenza B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cumulative occurrence rate of complications of grade ≥2
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of AEs leading to death
Endpoint domain: Adverse events/effects
Primary endpoint: Time until first rescue analgesic requirement postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI Biomarkers - Structural MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI Biomarkers - Diffusion Tensor MRI (DTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Activation Measure for Mental Health (PAM-MH)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with adverse events (AEs) of Grade 2 and above severity
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma-concentration time curve from time zero to infinity (AUC0-inf) of VH4527079
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of VH4527079
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary outcome measure 1
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Primary outcome measure 2
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Recruitment rate - referral
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recruitment rate - inclusion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recruitment rate - consent
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to HBOT protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to HBOT protocol - satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of Clinical Outcome Measures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Delivery of health behaviour change interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Objective response rate to CAR T-cell therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restorative criteria adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes